Laura A. Percy
London, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
A new prognostic model for myeloma patients relapsing from upfront autologous transplantation based on ISS and PFS1.
Journal: British journal of haematology
Published: July 10, 2018
Denying contraceptive choice to women with a previous ectopic pregnancy.
Journal: The journal of family planning and reproductive health care
Published: December 06, 2016
Commentary on 'Prescribing patterns of combined hormonal products containing cyproterone acetate, levonorgestrel and drospirenone in the UK'.
Journal: The journal of family planning and reproductive health care
Published: August 16, 2016
Iron deficiency and iron deficiency anaemia in women.
Journal: Best practice & research. Clinical obstetrics & gynaecology
Published: August 01, 2016
The new UK Medical Eligibility Criteria (UKMEC): what has changed?
Journal: The journal of family planning and reproductive health care
Published: February 28, 2016
Would an exclusively contraceptive clinic help meet the needs of patients attending an integrated sexual health service?
Journal: The journal of family planning and reproductive health care
Published: September 25, 2015
Cohort analysis of FISH testing of CD138(+) cells in relapsed multiple myeloma: implications for prognosis and choice of therapy.
Journal: British journal of haematology
Published: April 23, 2015
RAS mutation status and bortezomib therapy for relapsed multiple myeloma.
Journal: British journal of haematology
Published: January 13, 2015
The bone marrow stromal compartment in multiple myeloma patients retains capability for osteogenic differentiation in vitro: defining the stromal defect in myeloma.
Journal: British journal of haematology
Published: April 04, 2014
Tailoring oral contraceptive pills to meet the needs of women.
Journal: The journal of family planning and reproductive health care
Published: September 25, 2013
Weekly intravenous bortezomib is effective and well tolerated in relapsed/refractory myeloma.
Journal: European journal of haematology
Published: December 28, 2012
Re-infused lymphocyte dose does not influence disease control following upfront autologous stem cell transplantation for multiple myeloma.
Journal: British journal of haematology
Published: April 20, 2012
Last Updated: 09/26/2026